HB 1530, the Genetic Information Privacy Act, requires direct-to-consumer genetic testing companies operating in Pennsylvania to protect residents' genetic data. Companies must obtain clear, separate consent for data collection, use, sharing, and retention; implement security measures; and provide consumers with access to or deletion of their data. The bill specifically prohibits sharing genetic data with insurers, employers, or third parties without explicit written consent. Violations could result in $2,500 civil penalties per incident, enforced by the Attorney General’s office. The law applies to Pennsylvania residents and covers genetic data like DNA test results, but excludes research data collected under federal health privacy rules.
HB 1202 establishes Pennsylvania's Infectious Disease Advisory Commission to coordinate long-term responses to public health emergencies like pandemics. The bill requires the Governor to select a statewide organization via competitive bidding to manage a PPE stockpile, including sourcing from in-state manufacturers and maintaining four designated storage locations. It directly affects healthcare facilities (such as nursing homes, assisted living centers, and personal care homes) by mandating infectious disease plans and requiring facilities to designate coordinators for outbreak response. Key provisions include creating the Commission, defining emergency protocols, and ensuring PPE availability during health crises. The law focuses on systemic preparedness rather than specific pandemic responses.
HB 923 amends the State Lottery Law to redirect lottery revenue toward providing pharmaceutical assistance for elderly residents. It directly affects seniors who qualify for prescription drug aid under state programs by modifying eligibility determination procedures. The key provision updates how income and asset thresholds are calculated to determine who qualifies for this assistance. The bill became law on November 24, 2025, after approval by both legislative chambers and the governor.
SB 88 amends Pennsylvania's Insurance Company Law to require health insurance plans sold in the state to cover specific breast imaging services without cost-sharing for policyholders. It mandates annual mammograms for women 40+ and physician-recommended mammograms for women under 40, plus MRI and other breast imaging for those at average or higher risk of breast cancer due to factors like family history, genetic mutations, or dense breast tissue. The law specifies coverage for screening, supplemental, and diagnostic exams but does not require coverage for mastectomies or override standard deductibles/copays beyond the minimum required services. This replaces prior requirements that allowed cost-sharing and excluded MRI coverage.
The bill (HB 1715) amends Pennsylvania's Newborn Child Testing Act to enhance newborn screening and follow-up programs. It directly affects newborns, parents, and healthcare providers by updating requirements for screening tests and ensuring timely medical follow-up for infants with positive results. The bill's key provisions focus on improving the accuracy and efficiency of the screening process and strengthening coordination between healthcare facilities and public health agencies. As currently described in the provided context, the bill's specific policy changes beyond the title are not detailed. It is pending in the Health committee after being laid on the table.
HB 1652 adds Gaucher disease to Pennsylvania's mandatory newborn screening program under the Newborn Child Testing Act. The bill expands the existing program to require screening for this genetic disorder in newborns, directly affecting all infants born in Pennsylvania. Key provisions include updating the list of covered conditions under Section 3(a)(1) of the 1965 Act, ensuring healthcare providers screen for Gaucher disease to identify it early. This change aims to enable timely treatment to prevent intellectual or physical disabilities, aligning with the program's existing purpose. The bill does not alter funding or implementation processes, only adding one specific condition to the screening list.
HB 1043 amends Pennsylvania's Public School Code to expand access to emergency allergy and asthma treatments in schools. The bill specifically allows school staff, including bus drivers and crossing guards, to possess, use, and administer epinephrine auto-injectors (like EpiPens) and asthma inhalers for students in medical emergencies. It updates definitions and procedures to ensure authorized personnel can act quickly during allergic reactions or asthma attacks without requiring individual physician orders each time. This directly affects students with life-threatening allergies or asthma and school staff who may need to provide immediate care.
SB 715 extends the expiration date of Pennsylvania's Rare Disease Advisory Council from June 30, 2025, to June 30, 2028. This procedural bill directly affects the council, which advises state departments on rare disease issues, and the departments it collaborates with (Health, Insurance, Human Services, Education). The key provision simply changes the expiration date in the 2017 law without altering the council's structure or duties. This extension provides continued operation of the council for an additional three years.
SB 731 amends the existing Pharmaceutical Assistance Contract for the Elderly (PACE) program to add a new "Needs Enhancement Tier" for determining eligibility. This tier would allow more elderly residents to qualify for prescription drug assistance based on specific financial or health needs. The bill changes how eligibility is assessed under the program, making it easier for seniors with higher needs to access medication support. The bill recently passed final passage on November 12, 2025, and is now referred to Rules & Executive Nominations.
HB 446 requires hospitals and ambulatory surgical facilities in Pennsylvania to offer patients unused, facility-provided medication at no additional cost upon discharge, if the prescriber determines it's clinically appropriate for continuing treatment. The bill specifies that this applies only to non-controlled, multi-dose medications like eye drops, creams, or inhalers (excluding IV drugs or controlled substances), and mandates clear discharge instructions with usage details and contact information. Providers acting in good faith are protected from liability for patient misuse, and such medication offers are exempt from standard outpatient dispensing rules. This directly affects patients discharged from hospitals or ambulatory facilities and the healthcare facilities providing their care.
